Pharmaceutical News

The companies will focus on the development of biomarkers for chronic diseases Nordic Bioscience has announced the strengthening of its ongoing collaboration with Roche for the development of proprietary biomarkers involved in tissue breakdown and build-up. Nordic typically concentrates on extra cellular matrix biomarker development, providing objective decision-making for compound selection in clinical trials. As
0 Comments
In a recent study posted to the medRxiv* preprint server, researchers assessed whether non-invasive estimation of the ratio of arterial oxygen partial pressure (PaO2) to the fractional inspired oxygen (Fi O2), i.e., the P/F ratio could measure overt and occult hypoxemia in coronavirus disease 2019 (COVID-19) patients. Study: Overt and occult hypoxemia in patients hospitalized
0 Comments
A new perspective by researchers from the American Cancer Society (ACS) and the University of Texas Health Science Center at San Antonio shows the high burden of breast cancer mortality in African American (Black) women versus White women began in the United States in the 1980’s. At that time, breast cancer screening (mammography) and treatments
0 Comments
Therapy represents the first STAMP inhibitor for patients with chronic myeloid leukaemia Novartis UK has announced that Scemblix – also known as asciminib – has been granted marketing authorisation in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). The treatment involves patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic
0 Comments
Physicians at Stanford Medicine have developed a way to provide pediatric kidney transplants without immune-suppressing drugs. Their key innovation is a safe method to transplant the donor’s immune system to the patient before surgeons implant the kidney. The medical team has named the two-transplant combination a “dual immune/solid organ transplant,” or DISOT. A scientific paper
0 Comments
The MT-RNR1 test was assessed under NICE’s diagnostics assessment programme Genedrive – the near patient molecular diagnostics company – has revealed that the National Institute for Health and Care Excellence (NICE) has started an evaluation of the MT-RNR1 test via its Diagnostics Assessment Programme (DAP). Genedrive’s assay is the world’s first rapid point-of-care test to
0 Comments
In recent research posted to the bioRxiv* preprint server, investigators confirmed that human immunodeficiency virus (HIV) co-infection alters B cell reaction in coronavirus disease 2019 (COVID-19). Study: HIV skews the SARS-CoV-2 B cell response toward an extrafollicular maturation pathway​​​​​​​. Image Credit: Kateryna Kon / Shutterstock Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to challenge global health, specifically
0 Comments
The deal will boost CatSci’s ability to deliver best-in-class medicines to patients worldwide Keensight Capital has invested in CatSci – a contract research organisation (CRO) that supports leading pharma companies to deliver life-changing therapeutics to patients around the world. Based in Cardiff, CatSci was formed in 2010 from a spin-out of AstraZeneca’s Catalyst Screening Facility.
0 Comments
The three-year project will focus on molecular representations and computational tools Merck has announced a collaboration with the Mulliken Center for Theoretical Chemistry at the Rheinische Friedrich-Wilhelms-University of Bonn in Germany. The three-year partnership will focus on the development of new tools for computational chemistry modelling as well as new molecular representations to advance the
0 Comments
An international team of scientists, led by the University of Bristol, has been investigating how the SARS-CoV-2 virus, the coronavirus responsible for the COVID-19 pandemic, manipulates host proteins to penetrate into human cells. After identifying Neuropilin-1 (NRP1) as a host factor for SARS-CoV-2 infection, new findings published in the journal of the Proceedings of the
0 Comments
In a recent study posted to the bioRxiv* pre-print server, researchers analyzed two genomic sequences of the Monkeypox virus from Belgium and Portugal termed ITM001 and PT0001, respectively, to show that the May 2022 Monkeypox outbreak most likely originated from the West African clade of the virus. Moreover, these sequences were ~99% identical to Monkeypox
0 Comments
Vital dengue vaccine offers over four years’ protection following successful clinical trial Takeda has announced that its dengue vaccine, TAK-003, prevented 84% of hospitalised cases and 61% of symptomatic cases. Furthermore, there were no important safety risks identified among the overall population throughout the four and a half years following vaccination during the phase 3
0 Comments
Artificial intelligence (AI) can be used to identify thyroid nodules seen on thyroid ultrasound that are very unlikely to be cancerous, reducing a large number of unnecessary biopsies, according to a new study being presented Saturday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga. Thyroid nodules are very common. Fine needle aspiration
0 Comments
The partnership will involve the optimised delivery of saRNA-based vaccines and therapeutics Ziphius Vaccines and the University of Antwerp have announced that they have entered into a collaboration agreement to research and develop a dynamic lipid library for optimised delivery systems of ribonucleic acid (RNA) based drugs and therapeutics. Ziphus specialises in developing transformative self-amplifying
0 Comments
A mass survey of citizens aged 50 to 89 years examined whether cognitive decline could be detected by sagittal spinal balance measurement based on a radiological approach. Doctors from Shinshu University observed associations of sagittal vertical axis (SVA) anteriorization and higher age with lower cognitive function. The sagittal vertical axis is the length of a
0 Comments
The company completes its enrolment in phase 3 trial evaluating ensifentrine for treatment of COPD Verona has announced that it has completed patient enrolment – with more than 800 subjects involved – for its randomised ENHANCE-1 trial. The study will evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is a
0 Comments